AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00607477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: 25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
Study NCT02518698 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
Study NCT04577703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: CT053PTSA will be administered daily in fasting state
Study NCT00248235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00248235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT00851344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 (50mg)
Description: GSK835726 (50mg) tablet
Study NCT00851344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 (100mg)
Description: GSK835726 (100mg) tablet
Study NCT00851344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine (10mg)
Description: Cetirizine (10mg) tablet as positive control
Study NCT00851344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match active
Study NCT02595996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
Study NCT01154829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amisulpride
Description: Individually dosed, according to symptoms, for a period of 6 weeks
Study NCT01154829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: Individually dosed, according to symptoms, for a period of 6 weeks
Study NCT03012724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H7-Coil
Description: Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
Study NCT03012724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H1-Coil
Description: Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
Study NCT02284360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APOSEC™ for cutaneous use
Description: On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure.
Study NCT01882348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CEASE Intervention
Description: The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
Study NCT00468468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor
Description: computer based education and support
Study NCT05912660 — intervention group
Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Aortic Valve Replacement (surgically or TAVI)
Study NCT04143087 — intervention group
Intervention type: DRUG
Intervention: withdrawal TKIs or halve TKIs
Description: Stop TKIs or treated by half TKIs
Study NCT02994134 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise.
Description: Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
Study NCT02994134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise.
Description: High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
Study NCT05350306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chincup
Description: Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
Study NCT05350306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
Study NCT00805701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: avodart
Description: 0.5 avodart once daily for 13 weeks
Study NCT00805701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03989765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programme to reduce involuntary treatment episodes
Description: See description of trial arms
Study NCT03169686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavioral Intervention
Description: Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.
Study NCT02165371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sinovuyo Caring Families Programme
Description: Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa.
Study NCT01869881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag(Sarpogrelate)
Description: Sarpogrelate 100mg 2 tablets, bid, 400mg/day
Study NCT01869881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100mg 2 tablets, bid, 400mg/day
Study NCT02402829 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral Vein Blood draw
Description: Drawing blood through a peripheral vein in the arm.
Study NCT00200161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
Study NCT00200161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
Study NCT01502007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerometer feedback and lifestyle counseling
Description: Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
Study NCT01502007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerometer without Feedback
Description: The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
Study NCT06229639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passy Muir Valve
Study NCT03431337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg
Description: Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
Study NCT03431337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (lactase)
Description: Placebo (in place of additional amoxicillin in experimental arm)
Study NCT04592419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection
Study NCT04592419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection
Study NCT04592419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT04592419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study NCT01762228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
Study NCT01762228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRPV1 agonist
Description: Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
Study NCT03110380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet(s) administered orally once daily
Study NCT03110380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF
Description: 200/25 mg FDC tablet(s) administered orally once daily
Study NCT03110380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Description: 50 mg tablet(s) administered orally once daily
Study NCT03110380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG Placebo
Description: Tablet(s) administered orally once daily
Study NCT03110380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF Placebo
Description: Tablet(s) administered orally once daily
Study NCT03110380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablet(s) administered orally once daily
Study NCT02461238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers
Description: The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
Study NCT02700971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Microscope Diagnostic system
Description: Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
Study NCT02301533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shikamana Intervention
Description: See arm description
Study NCT02301533 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: See arm description
Study NCT03848858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR plus TAU
Description: The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
Study NCT02577133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
Study NCT02577133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consisted of an identical bottle with distilled water
Study NCT04073134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study NCT04073134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study NCT00630903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUVA (8MOP + UVA) + IFN
Description: Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
Study NCT00630903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUVA (8-MOP + UVA)
Description: Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
Study NCT00636324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal CPAP, level 7 to 9 cmH2O
Description: Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
Study NCT00636324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP, level 4 to 6 cmH2O
Description: Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
Study NCT01165476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treprostinil diethanolamine
Description: sustained release tablets. One 1mg tablet per period. Two total doses.
Study NCT01165476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil diethanolamine
Description: sustained release tablets. One 1mg tablet per period. Two total doses.
Study NCT02767947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1%
Description: Luliconazole cream will be applied per schedule specified in the arm.
Study NCT02767947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream will be applied per schedule specified in the arm.
Study NCT02805413 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Détermination and comparison of blood pressure
Description: Rebreathings will be performed every parabola (2, 4, 6, 8, 10...). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9...). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
Study NCT03039036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: Artificially rupturing membranes
Study NCT03039036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotomy
Description: Artificially rupturing membranes
Study NCT03039036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
Study NCT03039036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Catheter
Description: Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
Study NCT03039036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
Study NCT03039036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
Study NCT04000191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
Study NCT04000191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAC
Description: Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
Study NCT06229639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy Plug
Study NCT00199485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angelica Sinensis
Description: Angelica Sinensis / placebo